Conference Coverage
Conference Coverage
09/30/2024
Anthony Calabro, MA
In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...
09/30/2024
Conference Coverage
Conference Coverage
09/27/2024
Anthony Calabro, MA
Researchers who developed a meta-analysis of 19 randomized controlled trials found a statistically significant improvement in overall survival with sorafenib when compared with placebo for patients with...
09/27/2024
research summary
research summary
09/23/2024
Anthony Calabro, MA
Researchers conducted a meta-analysis examining the current evidence on the safety, efficacy, and predictive factors for venetoclax-based regimens in older adults with acute myeloid leukemia.
09/23/2024
Conference Coverage
Conference Coverage
09/19/2024
Jessica Ganga
In this retrospective study, researchers assessed the turnaround time of mutational tests in patients with newly diagnosed acute myeloid leukemia (AML) and the time from diagnosis to treatment initiation....
09/19/2024
research summary
research summary
03/26/2024

Leigh Precopio

Leigh Precopio
Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...
03/26/2024
research summary
research summary
11/30/2023
Leigh Precopio
Individuals with acute myeloid leukemia often have low levels of vitamin C and vitamin D at the time of diagnosis. Researchers examined how supplementation of these vitamins during treatment impacted...
11/30/2023
Research Summary
Research Summary
11/17/2023
Anthony Calabro, MA
Researchers set out to determine whether DNA sequencing of the blood from adults with acute myeloid leukemia in remission before allogeneic hematopoietic cell transplant could detect residual variant...
11/17/2023
Research Summary
Research Summary
10/26/2023
Anthony Calabro, MA
Researchers set out to determine the impact of midostaurin in adult patients with FLT3-mutated acute myeloid leukemia.
10/26/2023
fda alert
fda alert
10/19/2023
Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
Conference Coverage
Conference Coverage
09/29/2023
Anthony Calabro, MA
Researchers retrospectively identified patients with CNS AML and evaluated several treatments and outcomes for this type of cancer at two large academic institutions.
09/29/2023